{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T04:25:16Z","timestamp":1754195116172,"version":"3.41.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hangzhou Medical College Science and Technology Innovation Guidance Fund","award":["CX2022019","CX2022019","CX2022019","CX2022019","CX2022019"],"award-info":[{"award-number":["CX2022019","CX2022019","CX2022019","CX2022019","CX2022019"]}]},{"name":"General scientific research project of Education Department of Zhejiang Province, Hangzhou Medical College","award":["Y202249233","Y202249233","Y202249233","Y202249233","Y202249233"],"award-info":[{"award-number":["Y202249233","Y202249233","Y202249233","Y202249233","Y202249233"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"DOI":"10.1186\/s13019-025-03513-8","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T11:34:33Z","timestamp":1751715273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The combination of chemotherapy and immune checkpoint inhibitors in recurrent extensive-stage small cell lung cancer: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Chunxiu","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingtu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"3513_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3513_CR2","unstructured":"Foundation L. Types of Lung Cancer. [cited 2024 March]; Available from: https:\/\/lungevity.org\/for-patients-caregivers\/lung-cancer-101\/types-of-lung-cancer"},{"key":"3513_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-019-0736-3","volume":"12","author":"S Yang","year":"2019","unstructured":"Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019;12:47.","journal-title":"J Hematol Oncol"},{"key":"3513_CR4","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1200\/JCO.21.01639","volume":"40","author":"JA Bogart","year":"2022","unstructured":"Bogart JA, Waqar SN, Mix MD. Radiation and systemic therapy for Limited-Stage Small-Cell lung Cancer. J Clin Oncol. 2022;40:661\u201370.","journal-title":"J Clin Oncol"},{"key":"3513_CR5","doi-asserted-by":"publisher","first-page":"14881","DOI":"10.1002\/cam4.5843","volume":"12","author":"G Qiu","year":"2023","unstructured":"Qiu G, Wang F, Xie X, Liu T, Zeng C, Chen Z, et al. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer. Cancer Med. 2023;12:14881\u201391.","journal-title":"Cancer Med"},{"key":"3513_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3816\/CLC.2008.n.041","volume":"9","author":"J Allen","year":"2008","unstructured":"Allen J, Jahanzeb M. Extensive-stage small-cell lung cancer: evolution of systemic therapy and future directions. Clin Lung Cancer. 2008;9:262\u201370.","journal-title":"Clin Lung Cancer"},{"key":"3513_CR7","doi-asserted-by":"crossref","unstructured":"Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current Diagnosis and Management of Small-Cell Lung Cancer. Mayo Clin Proc. 2019; 94:1599\u2013\u2009622.","DOI":"10.1016\/j.mayocp.2019.01.034"},{"key":"3513_CR8","doi-asserted-by":"publisher","first-page":"100408","DOI":"10.1016\/j.esmoop.2022.100408","volume":"7","author":"L Paz-Ares","year":"2022","unstructured":"Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7:100408.","journal-title":"ESMO Open"},{"key":"3513_CR9","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1634\/theoncologist.12-9-1096","volume":"12","author":"BE Lally","year":"2007","unstructured":"Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist. 2007;12:1096\u2013104.","journal-title":"Oncologist"},{"issue":"Suppl 5","key":"3513_CR10","first-page":"S565","volume":"5","author":"BA Chan","year":"2013","unstructured":"Chan BA, Coward JI. Chemotherapy advances in small-cell lung cancer. J Thorac Dis. 2013;5(Suppl 5):S565\u201378.","journal-title":"J Thorac Dis"},{"key":"3513_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7:3.","journal-title":"Nat Rev Dis Primers"},{"key":"3513_CR12","first-page":"452","volume":"76","author":"A Paulus","year":"2021","unstructured":"Paulus A, Lousberg L, Duysinx B, Sibille A, Duquenne JB, Corhay JL, et al. [Small cell lung cancer: update of therapy]. Rev Med Liege. 2021;76:452\u20137.","journal-title":"Rev Med Liege"},{"key":"3513_CR13","doi-asserted-by":"publisher","first-page":"683318","DOI":"10.3389\/fonc.2021.683318","volume":"11","author":"L Ju","year":"2021","unstructured":"Ju L, Yang J, Zhai C, Chai S, Dong Z, Li M, Survival. Chemotherapy and chemosensitivity predicted by CTC cultured in vitro of SCLC patients. Front Oncol. 2021;11:683318.","journal-title":"Front Oncol"},{"key":"3513_CR14","doi-asserted-by":"crossref","unstructured":"Hiddinga BI, Raskin J, Janssens A, Pauwels P, Van Meerbeeck JP. Recent developments in the treatment of small cell lung cancer. Eur Respir Rev. 2021; 30.","DOI":"10.1183\/16000617.0079-2021"},{"key":"3513_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.21037\/tlcr.2019.10.21","volume":"8","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Wan B, Zhang T, Xu Y, Liu H, Lv T, et al. Irinotecan, topotecan, Paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis. Transl Lung Cancer Res. 2019;8:829\u201337.","journal-title":"Transl Lung Cancer Res"},{"key":"3513_CR16","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2009.26.7682","volume":"28","author":"DS Ettinger","year":"2010","unstructured":"Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010;28:2598\u2013603.","journal-title":"J Clin Oncol"},{"key":"3513_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1200\/JCO.2010.29.8851","volume":"29","author":"R Jotte","year":"2011","unstructured":"Jotte R, Conkling P, Reynolds C, Galsky MD, Klein L, Fitzgibbons JF, et al. Randomized phase II trial of single-agent amrubicin or Topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol. 2011;29:287\u201393.","journal-title":"J Clin Oncol"},{"key":"3513_CR18","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.21873\/invivo.11727","volume":"33","author":"K Wakuda","year":"2019","unstructured":"Wakuda K, Miyawaki T, Miyawaki E, Mamesaya N, Kawamura T, Kobayashi H, et al. Efficacy of Second-line chemotherapy in patients with sensitive relapsed Small-cell lung Cancer. Vivo. 2019;33:2229\u201334.","journal-title":"Vivo"},{"key":"3513_CR19","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1111\/1759-7714.13698","volume":"11","author":"S Zhang","year":"2020","unstructured":"Zhang S, Li S, Cheng Y. Efficacy and safety of PD-1\/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis. Thorac Cancer. 2020;11:3536\u201346.","journal-title":"Thorac Cancer"},{"key":"3513_CR20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with Extensive-Stage Small-Cell lung Cancer treated with atezolizumab, carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39:619\u201330.","journal-title":"J Clin Oncol"},{"key":"3513_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","volume":"21","author":"J Trigo","year":"2020","unstructured":"Trigo J, Subbiah V, Besse B, Moreno V, L\u00f3pez R, Sala MA, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21:645\u201354.","journal-title":"Lancet Oncol"},{"key":"3513_CR22","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, et al. Adebrelimab or placebo plus carboplatin and Etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:739\u201347.","journal-title":"Lancet Oncol"},{"key":"3513_CR23","doi-asserted-by":"publisher","first-page":"846597","DOI":"10.3389\/fonc.2022.846597","volume":"12","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Li Y, Dong Y, Li J, Zhang B, Zhang C, et al. Successful treatment of a patient with Multiple-Line relapsed Extensive-Stage Small-Cell lung Cancer receiving penpulimab combined with anlotinib: A case report. Front Oncol. 2022;12:846597.","journal-title":"Front Oncol"},{"key":"3513_CR24","doi-asserted-by":"crossref","unstructured":"Qu J, Kalyani FS, Shen Q, Yang G, Cheng T, Liu L et al. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study. J Oncol. 2022; 2022:3645489.","DOI":"10.1155\/2022\/3645489"},{"key":"3513_CR25","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","volume":"31","author":"A Ribas","year":"2013","unstructured":"Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing Tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31:616\u201322.","journal-title":"J Clin Oncol"},{"key":"3513_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51\u201365.","journal-title":"Lancet Oncol"},{"key":"3513_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.annonc.2019.10.021","volume":"31","author":"AS Mansfield","year":"2020","unstructured":"Mansfield AS, Ka\u017carnowicz A, Karaseva N, S\u00e1nchez A, De Boer R, Andric Z, et al. Safety and patient-reported outcomes of atezolizumab, carboplatin, and Etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I\/III trial. Ann Oncol. 2020;31:310\u20137.","journal-title":"Ann Oncol"},{"key":"3513_CR28","doi-asserted-by":"crossref","unstructured":"Deneka AY, Boumber Y, Beck T, Golemis EA. Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). Cancers (Basel). 2019; 11.","DOI":"10.3390\/cancers11091297"},{"key":"3513_CR29","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.21037\/apm-21-3860","volume":"11","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Zhang L, Zhu F, Zhu H, Cao X, Zhang Y. Camrelizumab combined with anlotinib for the treatment of small cell lung cancer: a case report and literature review. Ann Palliat Med. 2022;11:1135\u201346.","journal-title":"Ann Palliat Med"},{"key":"3513_CR30","doi-asserted-by":"publisher","first-page":"696010","DOI":"10.3389\/fonc.2021.696010","volume":"11","author":"S Zhang","year":"2021","unstructured":"Zhang S, Li S, Cui Y, Zhao P, Sun X, Cheng Y. Consideration of surrogate endpoints for overall survival associated with First-Line immunotherapy in Extensive-Stage small cell lung Cancer. Front Oncol. 2021;11:696010.","journal-title":"Front Oncol"},{"key":"3513_CR31","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"AC Dingemans","year":"2021","unstructured":"Dingemans AC, Fr\u00fch M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2606). Ann Oncol. 2021;32:839\u201353.","journal-title":"Ann Oncol"},{"key":"3513_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","volume":"385","author":"BJ Slotman","year":"2015","unstructured":"Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36\u201342.","journal-title":"Lancet"},{"key":"3513_CR33","first-page":"139","volume":"19","author":"X Shang","year":"2020","unstructured":"Shang X, Lin J, Li Z, Wang H. Radiotherapy May improve survival of ES-SCLC with distant metastasis only for patients with one metastatic site: A population-based study. Oncol Lett. 2020;19:139\u201346.","journal-title":"Oncol Lett"},{"key":"3513_CR34","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.6004\/jnccn.2018.0079","volume":"16","author":"GP Kalemkerian","year":"2018","unstructured":"Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, et al. NCCN guidelines insights: small cell lung cancer, version 2.2018. J Natl Compr Canc Netw. 2018;16:1171\u201382.","journal-title":"J Natl Compr Canc Netw"},{"key":"3513_CR35","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jtho.2019.01.010","volume":"14","author":"M Reck","year":"2019","unstructured":"Reck M, Horn L, Novello S, Barlesi F, Albert I, Juh\u00e1sz E, et al. Phase II study of roniciclib in combination with cisplatin\/etoposide or carboplatin\/etoposide as First-Line therapy in patients with Extensive-Disease small cell lung Cancer. J Thorac Oncol. 2019;14:701\u201311.","journal-title":"J Thorac Oncol"},{"key":"3513_CR36","doi-asserted-by":"publisher","first-page":"e27138","DOI":"10.1097\/MD.0000000000027138","volume":"100","author":"L Liu","year":"2021","unstructured":"Liu L, Zhang X, Zhou L, Yang T, Qiao Y, Jiang X. Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report. Med (Baltim). 2021;100:e27138.","journal-title":"Med (Baltim)"},{"key":"3513_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3892\/etm.2023.12012","volume":"26","author":"Y Wu","year":"2023","unstructured":"Wu Y, Chen Y, Yang Z. Toripalimab combined with anlotinib for recurrent extensive\u2013stage small\u2013cell lung cancer: A case report. Exp Ther Med. 2023;26:313.","journal-title":"Exp Ther Med"},{"key":"3513_CR38","doi-asserted-by":"publisher","first-page":"1111325","DOI":"10.3389\/fimmu.2023.1111325","volume":"14","author":"N Zhou","year":"2023","unstructured":"Zhou N, Chen Y, Huang Q, Jiang L, Liao H, Gou H, et al. Pathological complete response to neoadjuvant Tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review. Front Immunol. 2023;14:1111325.","journal-title":"Front Immunol"},{"key":"3513_CR39","first-page":"681","volume":"11","author":"H Liu","year":"2019","unstructured":"Liu H, Guo L, Zhang J, Zhou Y, Zhou J, Yao J, et al. Glycosylation-independent binding of monoclonal antibody Toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. MAbs. 2019;11:681\u201390.","journal-title":"MAbs"},{"key":"3513_CR40","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/2211-5463.13102","volume":"11","author":"Y Hong","year":"2021","unstructured":"Hong Y, Feng Y, Sun H, Zhang B, Wu H, Zhu Q, et al. Tislelizumab uniquely binds to the CC\u2019 loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. FEBS Open Bio. 2021;11:782\u201392.","journal-title":"FEBS Open Bio"},{"key":"3513_CR41","doi-asserted-by":"crossref","unstructured":"Desai J, Deva S, Lee JS, Lin CC, Yen CJ, Chao Y et al. Phase IA\/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. J Immunother Cancer. 2020; 8.","DOI":"10.1136\/jitc-2019-000453"},{"key":"3513_CR42","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam SJ. Toripalimab: first global approval. Drugs. 2019;79:573\u20138.","journal-title":"Drugs"},{"key":"3513_CR43","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1634\/theoncologist.2020-0193","volume":"25","author":"B Melosky","year":"2020","unstructured":"Melosky B, Cheema PK, Brade A, McLeod D, Liu G, Price PW, et al. Prolonging survival: the role of immune checkpoint inhibitors in the treatment of Extensive-Stage small cell lung Cancer. Oncologist. 2020;25:981\u201392.","journal-title":"Oncologist"},{"key":"3513_CR44","doi-asserted-by":"publisher","first-page":"9267","DOI":"10.21037\/apm-21-858","volume":"10","author":"Y Qu","year":"2021","unstructured":"Qu Y, Wang Z, Feng J, Wang L, Liu H, Liu D, et al. Pneumonitis, appendicitis, and biliary obstruction during Toripalimab treatment in a patient with extensive-stage small-cell lung cancer: a case report. Ann Palliat Med. 2021;10:9267\u201375.","journal-title":"Ann Palliat Med"},{"key":"3513_CR45","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III Non-Small-Cell lung Cancer. N Engl J Med. 2017;377:1919\u201329.","journal-title":"N Engl J Med"},{"key":"3513_CR46","doi-asserted-by":"publisher","first-page":"e1524695","DOI":"10.1080\/2162402X.2018.1524695","volume":"8","author":"DY Wang","year":"2019","unstructured":"Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, et al. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology. 2019;8:e1524695.","journal-title":"Oncoimmunology"},{"key":"3513_CR47","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/annonc\/mdw649","volume":"28","author":"F Gelsomino","year":"2017","unstructured":"Gelsomino F, Vitale G, D\u2019Errico A, Bertuzzi C, Andreone P, Ardizzoni A. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol. 2017;28:671\u20132.","journal-title":"Ann Oncol"},{"key":"3513_CR48","doi-asserted-by":"publisher","first-page":"109275","DOI":"10.1016\/j.ejrad.2020.109275","volume":"132","author":"H Park","year":"2020","unstructured":"Park H, Hatabu H, Ricciuti B, Aijazi SJ, Awad MM, Nishino M. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. Eur J Radiol. 2020;132:109275.","journal-title":"Eur J Radiol"},{"key":"3513_CR49","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522\u201330.","journal-title":"Lancet Oncol"},{"key":"3513_CR50","doi-asserted-by":"publisher","first-page":"e7188","DOI":"10.1002\/cam4.7188","volume":"13","author":"T Nishimura","year":"2024","unstructured":"Nishimura T, Fujimoto H, Fujiwara T, Ito K, Fujiwara A, Yuda H, et al. Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors. Cancer Med. 2024;13:e7188.","journal-title":"Cancer Med"},{"key":"3513_CR51","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse events following Cancer immunotherapy: Obstacles and opportunities. Trends Immunol. 2019;40:511\u201323.","journal-title":"Trends Immunol"},{"key":"3513_CR52","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related adverse events associated with immune checkpoint Blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"3513_CR53","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.7150\/ijms.58415","volume":"18","author":"L Lu","year":"2021","unstructured":"Lu L, Zha Z, Zhang P, Li D, Liu G. NSE, positively regulated by LINC00657-miR-93-5p axis, promotes small cell lung cancer (SCLC) invasion and epithelial-mesenchymal transition (EMT) process. Int J Med Sci. 2021;18:3768\u201379.","journal-title":"Int J Med Sci"},{"key":"3513_CR54","doi-asserted-by":"publisher","first-page":"101039","DOI":"10.1016\/j.tranon.2021.101039","volume":"14","author":"Z Zha","year":"2021","unstructured":"Zha Z, Li D, Zhang P, Wang P, Fang X, Liu X, et al. Neuron specific enolase promotes tumor metastasis by activating the Wnt\/\u03b2-catenin pathway in small cell lung cancer. Transl Oncol. 2021;14:101039.","journal-title":"Transl Oncol"},{"key":"3513_CR55","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2018.02.017","volume":"119","author":"D Fujimoto","year":"2018","unstructured":"Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, et al. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. Lung Cancer. 2018;119:14\u201320.","journal-title":"Lung Cancer"},{"key":"3513_CR56","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1016\/j.cllc.2020.02.013","volume":"21","author":"R Rittberg","year":"2020","unstructured":"Rittberg R, Green S, Aquin T, Bucher O, Banerji S, Dawe DE. Effect of hospitalization during first chemotherapy and performance status on Small-cell lung Cancer outcomes. Clin Lung Cancer. 2020;21:e388\u2013404.","journal-title":"Clin Lung Cancer"},{"key":"3513_CR57","doi-asserted-by":"publisher","first-page":"175883592210971","DOI":"10.1177\/17588359221097191","volume":"14","author":"JA Stratmann","year":"2022","unstructured":"Stratmann JA, Timalsina R, Atmaca A, Rosery V, Frost N, Alt J, et al. Clinical predictors of survival in patients with relapsed\/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis. Ther Adv Med Oncol. 2022;14:17588359221097191.","journal-title":"Ther Adv Med Oncol"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-025-03513-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-025-03513-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-025-03513-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T13:02:33Z","timestamp":1751720553000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiothoracicsurgery.biomedcentral.com\/articles\/10.1186\/s13019-025-03513-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3513"],"URL":"https:\/\/doi.org\/10.1186\/s13019-025-03513-8","relation":{},"ISSN":["1749-8090"],"issn-type":[{"type":"electronic","value":"1749-8090"}],"subject":[],"published":{"date-parts":[[2025,7,5]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Quzhou Hospital of Zhejiang Medical and Health Group(Zhejiang Quhua Hospital)(2024-2).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"286"}}